Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.
포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.
터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
MGX-001 in Hemophilia A Advances Towards US and Ex-US Regulatory Interactions in 2025 NHP Proof-of-Concept...
EMERYVILLE, Calif., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic...
EMERYVILLE, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic...
MGX-001, utilizing a highly specific and efficient MG29-1 nuclease, exhibits no identifiable off-target editing...
Therapeutically relevant levels of Factor VIII (FVIII) activity sustained in ongoing nonhuman primate (NHP...
The Gross Law Firm Notifies Metagenomi, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline...
November 25, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against MGX PR Newswire NEW...
Investors who lost money on Metagenomi, Inc.(MGX) should contact The Gross Law Firm about pending Class Action...
Class Action Filed Against Metagenomi, Inc. (MGX) Seeking Recovery for Investors - Contact The Gross Law...
Initiating IND-enabling activities for MGX-001 development candidate (DC) in hemophilia A; Achieved durable...
Shareholders that lost money on Metagenomi, Inc.(MGX) should contact The Gross Law Firm about pending Class...
귀하가 조회한 주식이 이 박스에 나타나며 쉽게 최근 시세로 돌아갈 수 있습니다.
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관